ArticleStem cell reviews and reports2026
Bioprinted Human Umbilical Cord Mesenchymal Stem Cell-laden Microfiber-derived Extracellular Vesicles Promote Endometrial Repair and Fertility Recovery in Intrauterine Adhesions.
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Intrauterine adhesions (IUAs) pose a significant reproductive health challenge, often leading to infertility and complications in pregnancy owing to endometrial damage and fibrosis. Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) therapy has emerged as a potential strategy for endometrial repair. However, traditional EVs production methods yield low quantities with limited efficacy, hindering their widespread application. In this study, we proposed an innovative approach that integrates three-dimensional (3D) bioprinted human umbilical cord MSC microfiber-derived EVs (3D-EVs) with gelatin methacrylate hydrogels for in situ delivery. Our platform achieved a 1,000-fold increase in 3D-EV particles production and superior cargo quality compared with conventional 2D cultures. In a rat endometrial organoid injury model, 3D-EVs and 2D-EVs exhibited equivalent therapeutic efficacy. 3D-EVs promoted cell activity and inhibited cell damage by transferring decorin, which inhibited LPS-induced p38 phosphorylation. In vivo, 3D-EVs improved pregnancy outcomes by reducing endometrial fibrosis and promoting endometrial proliferation. Our findings suggest that 3D-EVs derived from bioprinted human umbilical cord MSC-laden microfibers mitigate endometrial injury and fibrosis, improving pregnancy outcomes in IUAs. This study opens new avenues for the development of effective EV-based therapies for the treatment of IUAs.
Indexed as
Identifiers
42234345What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.